SEER Stock Overview
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Seer, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.75 |
| 52 Week High | US$5.65 |
| 52 Week Low | US$1.46 |
| Beta | 1.65 |
| 1 Month Change | -8.85% |
| 3 Month Change | 8.70% |
| 1 Year Change | -52.45% |
| 3 Year Change | -96.55% |
| 5 Year Change | n/a |
| Change since IPO | -96.90% |
Recent News & Updates
Recent updates
Seer, Inc. (NASDAQ:SEER) Just Reported, And Analysts Assigned A US$7.00 Price Target
Mar 02
Newsflash: Seer, Inc. (NASDAQ:SEER) Analysts Have Been Trimming Their Revenue Forecasts
Nov 17We're Not Very Worried About Seer's (NASDAQ:SEER) Cash Burn Rate
May 19Companies Like Seer (NASDAQ:SEER) Are In A Position To Invest In Growth
Feb 06Analysts Have Lowered Expectations For Seer, Inc. (NASDAQ:SEER) After Its Latest Results
Nov 11Seer (NASDAQ:SEER) Is In A Good Position To Deliver On Growth Plans
Sep 15Seer stock tumbles aftermarket despite in-line Q2 earnings
Aug 09Companies Like Seer (NASDAQ:SEER) Are In A Position To Invest In Growth
Jun 02We Think Seer (NASDAQ:SEER) Can Afford To Drive Business Growth
Jan 17Seer: First Pick In Proteomics Portfolio
Sep 18Seer (NASDAQ:SEER) Is In A Good Position To Deliver On Growth Plans
Aug 30Sizing Up Seer
Jul 12We're Not Very Worried About Seer's (NASDAQ:SEER) Cash Burn Rate
May 13Seer reports Q1 results
May 10Is Seer, Inc. (NASDAQ:SEER) Popular Amongst Insiders?
Mar 04Seer, Bruker sign commercial agreement for proteomics
Jan 11Shareholder Returns
| SEER | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.2% | -4.9% | -3.7% |
| 1Y | -52.4% | -4.3% | 20.5% |
Return vs Industry: SEER underperformed the US Life Sciences industry which returned -4.3% over the past year.
Return vs Market: SEER underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| SEER volatility | |
|---|---|
| SEER Average Weekly Movement | 8.4% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SEER has not had significant price volatility in the past 3 months.
Volatility Over Time: SEER's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 147 | Omid Farokhzad | seer.bio |
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes.
Seer, Inc. Fundamentals Summary
| SEER fundamental statistics | |
|---|---|
| Market cap | US$109.47m |
| Earnings (TTM) | -US$86.28m |
| Revenue (TTM) | US$16.66m |
6.8x
P/S Ratio-1.3x
P/E RatioIs SEER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEER income statement (TTM) | |
|---|---|
| Revenue | US$16.66m |
| Cost of Revenue | US$8.16m |
| Gross Profit | US$8.51m |
| Other Expenses | US$94.78m |
| Earnings | -US$86.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.33 |
| Gross Margin | 51.05% |
| Net Profit Margin | -517.84% |
| Debt/Equity Ratio | 0% |
How did SEER perform over the long term?
See historical performance and comparison